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Dear Editor
Strategies aimed at managing human immunodeficiency virus (HIV)-infected 
and AIDS patients have been well-succeeded in decreasing morbidity and mortality 
due to the disease, whose worldwide estimated numbers reached 38 million 
people in 20181. Brazil introduced its HIV/ AIDS program in 1996, consisting of 
multidisciplinary monitoring and treatment for all known people living with HIV. 
In addition, screening and monitoring tests are available using the Brazilian health 
system (SUS). Furthermore, campaigns aimed at preventing new infections, focused 
on safe sex with the use of condoms and other practices have been implemented with 
variable success, as well as the antiretroviral therapy free of charge for treatment and 
more recently, as a prevention strategy2. Estimates point to 900,000 persons living 
with HIV in the country, 590,000 on antiretroviral treatment (ART) and 550,000 
of them with suppressed viral loads levels3.
We implemented a multidisciplinary care for HIV/AIDS people in our outpatient 
clinic, where we have cared for 800 patients from its inception, in 1983. Four 
hundred and thirty (55%) of these patients are still been followed-up4, one of 
them with more than 30 years of active follow-up. Since 1996, when Brazilian 
HIV/ AIDS program was implemented, with widely guided ART, the total mortality 
of our patients declined and reached six percent. The mean follow-up time of our 
cohort is 13 years, and all but six of our currently followed-up patients are not on 
antiretroviral therapy by their own choice. Thus, the adherence level is higher than 
95 percent; the latter was measured as the total amount of pills taken during the 
week before evaluation5.
We have some hypotheses to explain our successful strategy, such as:
1.  Our outpatient clinic located at Hospital das Clinicas, Faculdade de Medicina 
da Universidade de Sao Paulo, has a long experience in HIV-patients’ care, 
of more than 30 years; illustrating this, a few of our patients that still remain 
in the clinic are part of the “original” ones, from the inception of the service. 
The mortality rate in this cohort was approximately six percent in these 
30 years6;
2.  We have a pre-medical appointment team is composed of two nurses, a 
nutritionist and a psychotherapist. It is possible that this approach is helping 
the early identification of comorbidities, such as hypertension, renal diseases, 
obesity, smoking, risk of falls and bone fractures, as well as the adherence to 
the follow-up, treatment and medications;
3.  Since adherence would be the major challenge for some specific groups of 
patients, an easy and practical questionnaire is applied to all patients6. There 
is also a direct mobile phone number line exclusive to these patients and their 
relatives;
4.  For the routine medical care, we count on six infectious disease specialists and 
two senior clinical consultants, highly experienced on the discussion of clinical 
cases;
5.  Depression and anxiety are managed by experienced and motivated 
psychologists, aiming at preventing the further worsening of symptoms, caring 
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for the patients who were identified during regular 
medical consultation;
6.  Adherence issues are managed in small groups of up 
to five patients, with the supervision of a therapist, 
sometimes including a discussion wheel to improve the 
patients’ adherence to ART7. For most of these patients, 
when needed, antidepressive and/ or anti-anxiety 
medications are used. More severe cases are managed 
by a psychiatrist;
7.  During the regular follow-up, HIV-1 plasma viral load 
(PVL) and CD4 T-cells counts are routinely performed 
every six months, along with pre-ART genotyping tests. 
The surveillance of drug failure is requested for all 
patients with viral load levels higher than 200 copies/mL, 
which is the detection limit in our laboratory. The 
genotyping test may guide the ART decision, raising the 
possibility to choose more effective treatment regimens.
Figure 1 shows the algorithm used in our clinic in 
the last two decades. Despite all the strategies described 
above, among 430 patients are on active follow-up, 401 of 
them presented viral load levels below the detectable limit 
(< 40 copies/mL). Patients with viral load levels higher 
than 40 copies/mL (29 cases) were contacted by the 
nurse and an extra appointment was scheduled. Most of 
them showed up, they were re-tested and an adherence 
questionnaire was applied. During the extra appointment, 
nurse, psychologist, nutritionist and infectious diseases 
specialist (ID) were present. We had a total of three visits 
of failure cases for samples recollection and meeting with 
these cases. From the potential 29 patients, 23 showed up 
for the extra appointments: 14 cases had already a viral load 
< 40 copies/mL; and nine patients presented viral load 
levels over this limit of detection. The lack of adherence 
was the major problem, which we addressed and discussed 
with them, suggesting possible strategies to improve their 
motivation to adhere to the clinic and treatment. 
Figure 2 shows the evolution of resistance to 
antiretroviral drugs, characterized as a viral load higher 
than 200 copies/mL, throughout the follow-up time and 
according to the proportion of patients still remaining in the 
cohort. It is possible to observe that the proportion of viral 
load levels below 200 copies/ mL was inversely correlated 
to the number of genotyping tests (Figure 2) and directed 
correlated to the adherence. However, the most important 
would be to restore the immune response, crucial to prevent 
cancers and opportunistic infections. Indeed, there was a 
strong recovery of the T CD4+ cells, with only a few cases 
with values below 350 cells/ mm3, considered the limit for 
immune dysfunction among our patients.
How can we explain the success of our long-term 
strategy? The multidisciplinary team approach and 
Figure 1 - Algorithm used to define successful strategies to reach HIV control.
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improved, simpler-to-take new ART drugs such as 
integrase inhibitors may be the keys of our good results. 
However, despite that success in a clinical point of 
view, new challenges are still on the way, such the onset 
of cardiovascular diseases8, 6Vitamin D deficiency9, 
depression/ anxiety10,11, osteopenia/ osteoporosis12. More 
recent challenges are the development of HIV-associated 
neurological diseases (HAND), which were found in almost 
40% of patients on active follow-up. These conditions may 
impact the adherence to treatment and the patients may 
present with lack of ART efficacy that should be checked by 
genotyping tests13, higher viremia, and drop in T CD4+ cells 
counts, leading to higher morbidity and mortality3. These 
are the issues to be addressed in the near future, and again 
a multidisciplinary approach would be more up to the task.
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